Serine News and Research

RSS

Study identifies novel gene that controls nerve conduction velocity linked with MS

A new study published in The American Journal of Pathology identifies a novel gene that controls nerve conduction velocity.

13 Aug 2014

Metabolic pathway genes linked to AMD and choroidal vasculopathy

The cholesteryl ester transfer protein gene appears to increase susceptibility to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy, research shows.

1 Jul 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

New hope for people suffering from depression

There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists- (ASA-).

17 Jun 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

Researchers identify target molecules for development of new allergy drugs

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has recently published an extensive review article on the prospects of drug therapy for allergy. Completed in a large-scale EU project, the lead author of the review article is Professor Ilkka Harvima of the University of Eastern Finland and Kuopio University Hospital.

13 May 2014

Researchers identify several target molecules suitable for development of new allergy drugs

13 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer.

15 Apr 2014

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

Splicing findings offer lung cancer clues

Researchers from Spain have identified several new splicing events regulated by the oncogenic splicing factor SRSF1 in lung cancer, suggesting that their dysregulation is involved in the pathogenesis of the disease.

4 Feb 2014

TSRI scientists identify compound that shows promise for treating obesity-linked diabetes

Scientists at The Scripps Research Institute (TSRI) have demonstrated a drug-discovery strategy with a double payoff-it enables the rapid selection of chemical compounds that have a desired effect on cells and also highlights how the compounds work.

23 Dec 2013

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013

Reduced SMG1 protein expression may contribute to neurological disorders

The absence of a protein called SMG1 could be a contributing factor in the development of Parkinson's disease and other related neurological disorders, according to a study led by the Translational Genomics Research Institute.

31 Oct 2013

Researchers discover inherited gene mutation linked to childhood leukemia

Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia occurring in multiple relatives in individual families. The discovery of the PAX5 gene mutation was led by St. Jude Children's Research Hospital and others. The work appears in the current advance online edition of the scientific journal Nature Genetics.

11 Sep 2013

Researchers investigate importance of STAT1 phosphorylation in NK cells

Since its discovery in the early 1990s, the protein STAT1 (Signal Transducer and Activator of Transcription 1) has been found to be central in passing signals across immune cells, ensuring that our bodies react quickly and appropriately to threats from viruses or other pathogens.

7 Sep 2013

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

Cancer-linked mitosis: an interview with Professor Scott Kern, Johns Hopkins University School of Medicine

Mitosis is the process by which a cell gives rise to two daughter cells. It’s the basis behind the growth of the human body, the renewal of the human body as it ages, and unfortunately, the growth of cancers.

7 Aug 2013